John Greally

Dr. John Greally is a tenured Professor in the Departments of Genetics (Chief, Division of Genomics), Medicine (Division of Hematology) and Pediatrics (Division of Genetics) at the Albert Einstein College of Medicine, where he has been on faculty since 2001.  He was also the first Affiliate Member appointed at the New York Genome Center.

A native of Galway, Ireland, Dr. Greally received his honours degree in Medicine from the National University of Ireland in Galway in 1988, subsequently moving to the Children’s Hospital of Pittsburgh for Pediatrics residency and Yale University in 1993 for subspecialty training in Clinical Genetics.

He received his higher degrees in medicine (D.Med.) and science (Ph.D.) degrees from the National University of Ireland, Galway.  He was awarded his Fellowship of the American College of Medical Genetics (FACMG) in 2013. 

He is the Founding Director of the Center for Epigenomics at Einstein, where he holds the endowed position of Faculty Scholar for Epigenomics. 

He has been the recipient of numerous scholarships and awards, most recently the 2015-2016 Litchfield lectureship with title from the University of Oxford. 

He has over 160 publications and has released several software packages developed by his group as Bioconductor resources.  He is the recipient of numerous National Institutes of Health (NIH) and other grant awards. 

He serves on scientific advisory boards for the Singapore Institute for Clinical Sciences (SICS) and the NIH (NIEHS) TaRGET II Consortium Steering Committee, and has been a member of an Údarás na hOllscoile (the Governing Body) of the National University of Ireland, Galway since 2013.  He chaired the NIH study section Genetics of Health and Disease (GHD) from 2012-2014, and is a Section Editor (Epigenetics) for PLOS Genetics and on the editorial board of Epigenetics & Chromatin

He is an active clinician, with hospital privileges at Montefiore Medical Center in the Bronx, where he is an attending physician seeing patients referred for genetic problems.  He is part of the NIH’s CSER Consortium, developing software tools to enhance patient diagnostic success, clinical decision support and reverse phenotyping,

His basic science research is focused on the use of genomics techniques to understand human disease pathogenesis, described as somatic cellular genomics, specifically looking at cellular epigenetic models of reprogramming and cell subtype compositional changes.  He is currently writing a textbook on Epigenetics: History, Mechanism and Disease.